Is Taysha Gene Therapies, Inc. (TSHA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.0% / 30% | 11.1% / 30% | 0.0% / 30% | 83.28% / 5% | ✗ NOT HALAL |
| DJIM | 5.0% / 33% | 11.1% / 33% | 0.0% / 33% | 83.28% / 5% | ✗ NOT HALAL |
| MSCI | 39.4% / 33% | 86.7% / 33% | 0.0% / 33% | 83.28% / 5% | ✗ NOT HALAL |
| S&P | 5.0% / 33% | 11.1% / 33% | 0.0% / 33% | 83.28% / 5% | ✗ NOT HALAL |
| FTSE | 39.4% / 33% | 86.7% / 33% | 0.0% / 50% | 83.28% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -516.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -68.5% | |
| Return on Assets (ROA) | -27.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$81M |
| Free Cash Flow | -$82M |
| Total Debt | $63M |
| Debt-to-Equity | 28.4 |
| Current Ratio | 12.2 |
| Total Assets | $160M |
Price & Trading
| Last Close | $4.32 |
| 50-Day MA | $4.59 |
| 200-Day MA | $4.00 |
| Avg Volume | 2.6M |
| Beta | 1.1 |
|
52-Week Range
$1.05
| |
About Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Taysha Gene Therapies, Inc. (TSHA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Taysha Gene Therapies, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Taysha Gene Therapies, Inc.'s debt ratio?
Taysha Gene Therapies, Inc.'s debt ratio is 5.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 39.4%.
What are Taysha Gene Therapies, Inc.'s key financial metrics?
Taysha Gene Therapies, Inc. has a market capitalization of $1.2B, and revenue of $8M. Return on equity stands at -68.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.